Serveis preclínics i clínics: conforme a GLP i GCP

Bioanàlisi de petites molècules i genèrics

ESTUDIS DE BIOEQUIVALÈNCIA

BIOANÀLISI I IMMUNOGENICITAT DE BIOLOGIA I BIOSIMILARS

BIOANÀLISI D’ÀCIDS NUCLEICS

AVALUACIÓ I ESTADÍSTICA PK

ABSORCIÓ PERCUTANIA

Activitats enzimàtiques

HISTOPATOLOGIA

Testimonials

“We are currently developing multiple new biosimilar projects and consider Kymos one of the best CROs in Europe for drug release and testing.”

Yong Suk Yang, Global QC Operation Team Manager, CELLTRION, INC

“We were positively impressed when Kymos reacted to our needs by investing in their stability capabilities, and now, two years down the line, with projects in full-swing, I can safely say that we made the right choice. In Kymos we have found a reliable, committed, trustworthy and professional partner.”

Dr. Dino Mangion, Head of Malta Operations, MEDICHEM/COMBINO PHARMA Ltd

“Back in 2017 there weren’t many analytical CROs able to carry out Franz cell assays and Kymos’ pioneering work was pivotal for the registration of our product.”

Dr. Marius Strunk, Senior Pharmaceutical Development Manager, HELM AG

“Kymos offered superior historical expertise by being exposed to so many different clients, pharmacological compounds, and therapeutic areas. They addressed and anticipated very diverse problems.”

Dr. Pablo Avilés, PHARMAMAR SA

“I have had a long and fruitful experience with Kymos and have a huge interest in their participation owing to their reliability.”

Jaime Algorta, Medical Affairs Director, EXELTIS HEALTHCARE SLU

“Prolytic is our analytical partner throughout the entire drug development process. Such a long and complex process requires a laboratory you can trust. Professional yet flexible, Prolytic accompanies us through the preclinical and clinical phases.”

“Establishing robust miRNA methods for valuable results is tricky. The team at Prolytic have been a key collaboration partner. With their 30 years of experience in bioanalytics and broad know-how in different techniques, study types, and substance groups, we were able to quickly develop a reproducible and reliable analysis method for miRNAs.”

Dr. Meike Saul, Research Group Leader, Universitat Tècnica de Darmstadt

Get in touch

  • KOREA PHARM & BIO: Goyang, KR | 23-26 abril 2024

  • BIO KOREA 2024: Seül, KR | 08-10 de maig de 2024

  • BIO International Convention: San Diego, US | 3-6 juny 2024

  • Congrès POLEPHARMA Biotesting: Évreux, FR | 5-6 juny 2024

  • AFI Symposium: Rimini, IT | 5-7 juny 2024

  • BIOPLUS – INTERPHEX KOREA: Seül, KR | 10-12 de juliol de 2024

  • Farmaforum: Madrid, ES | 25-26 setembre 2024

  • Biomarkers Europe 2024: Basilea, CH | 30 de setembre – 01 d’octubre de 2024

  • CPHI 2024: Milan, IT | 8-10 octubre 2024

  • BIO-Europe Autumn: Estocolm, SE | 4-6 novembre 2024

  • European Bioanalysis Forum: Barcelona, ​​ES | 20-22 de novembre de 2024

  • TIDES Europe: Hamburg, DE | 12-14 novembre 2024

  • PharmaLab Congress: Düsseldorf, DE | 25-27 novembre 2024

  • I4ID 2024: Lyon, FR | 27-28 novembre 2024

    Laboratoris

    logotip de Kymos

    Barcelona
    Espanya

    logotip de Prolytic

    Frankfurt
    Alemanya

    logotip de Pharmaprogress

    Ancona
    Itàlia

    Oficines

    icon ofice samall

    París
    França

    icon ofice samall

    Milà
    Itàlia

    Branques

    logotip de Kymos per a la sucursal de KR

    Seül
    Corea